ALLERGAN ANNOUNCES FDA APPROVAL OF JUVÉDERM™ GEL ...

ALLERGAN ANNOUNCES FDA APPROVAL OF JUVÉDERM GEL FAMILY OF PRODUCTS FOR
THE TREATMENT OF FACIAL WRINKLES AND FOLDS
- ‘Next Generation’ Smooth Gel, Non-Animal Dermal Fillers Offer Natural,
Long-Lasting Results -
(IRVINE, Calif., June 5, 2006) – Allergan, Inc. (NYSE: AGN), the makers of BOTOX ® Cosmetic
(Botulinum Toxin Type A), today announced the U.S. Food and Drug Administration (FDA)’s approval
of the JUVÉDERM dermal filler gel family of products, a ‘next generation’ of hyaluronic acid dermal
fillers that provide a smooth, long-lasting correction of facial wrinkles and folds. Proprietary,
technologically advanced formulations of JUVÉDERM result in a smooth, natural look and contain
the highest concentration of non-animal and cross-linked hyaluronic acid of any dermal filler currently
available. These unique attributes provide optimal results with a single treatment in the majority of
patients and deliver sustained results for up to six months or longer.
“We are excited to offer physicians and patients JUVÉDERM dermal filler, the next generation
smooth gel hyaluronic acid formulations approved by the FDA as an important new option for the
correction of facial wrinkles and folds,” said Scott M. Whitcup, M.D., Allergan’s Executive Vice
President, Research and Development. “The unique gel formulation of JUVÉDERM is easy to inject
and provides a long-lasting clinical result.”
With the FDA approval, JUVÉDERM dermal filler joins BOTOX ® Cosmetic and an array of other
dermal filler and skin care treatments in Allergan’s facial aesthetics portfolio, which provides patients
and physicians with the most comprehensive total facial rejuvenation product offering available.
JUVÉDERM is natural, biodegradable and currently the only approved hyaluronic acid dermal filler
that has demonstrated its safety and effectiveness in patients of all skin types and colors. It also is
the only hyaluronic acid dermal filler developed using a proprietary, technologically advanced
manufacturing process that results in a malleable smooth gel that flows easily into the skin, creating a
smooth, natural look and feel. All other currently approved hyaluronic acid dermal fillers utilize a gel
particle suspension formulation.
“It is very exciting to have a new facial rejuvenation tool with the unique qualities of JUVÉDERM that
we can now offer to our patients. Our clinical investigation found JUVÉDERM dermal filler to be a
smooth-flowing injection that provides our patients with a natural appearing result. The new
formulation of hyaluronic acid offers physicians a high level of control for facial contouring,” said Gary
Monheit, M.D., Total Skin & Beauty Dermatology Center, P.C.; Associate Clinical Professor,
Department of Dermatology and Ophthalmology, University of Alabama at Birmingham; and
JUVÉDERM Clinical Investigator.
The JUVÉDERM dermal filler family of products offers the highest concentration of cross-linked
hyaluronic acid available in a dermal filler, which results in a long duration of effect and may be
attributed to the majority of patients not requiring touch-ups following their initial treatment. The
smooth consistency of the JUVÉDERM formula also may help to minimize the discomfort that can
sometimes occur during the injection procedure.
The FDA approved three different formulations for JUVÉDERM dermal filler providing physicians
with the flexibility to tailor each treatment to the particular needs of the patient. The three product
formulations include: JUVÉDERM 24HV, a highly cross-linked formulation for more versatility in

contouring and volumizing of facial wrinkles and folds; JUVÉDERM 30HV dermal filler, a more
highly cross-linked robust formulation for volumizing and correction of deeper folds and wrinkles; and
JUVÉDERM 30, a highly cross-linked formulation for subtle correction of facial wrinkles and folds.
Our presentation of the products, including the package and accessories, is currently being finalized
and availability dates are expected to be announced later in 2006. Physicians and consumers are
encouraged to visit www.JuvedermComingSoon.com to receive updates on product availability.
Hyaluronic acid dermal fillers represent the fastest growing non-invasive aesthetic procedure in the
United States and BOTOX ® Cosmetic has been the number one physician-administered, non-surgical
cosmetic procedure in the United States since 2002, according to the American Society for Aesthetic
Plastic Surgery. Occurring naturally in the body, hyaluronic acid is a natural complex sugar found in
all living organisms and creates volume and elasticity in the skin. JUVÉDERM adds volume to facial
wrinkles, such as nasolabial folds (the folds running from the sides of the bottom of the nose to the
outer corners of the mouth). BOTOX ® Cosmetic works differently -- by relaxing the dominant frown
muscles between the eyebrows (the glabellar area). This allows the two vertical lines between the
brows, often referred to as the “11,” to temporarily diminish in appearance. Like BOTOX ® , which has
been available for more than 16 years and is currently approved to treat 20 different medical
conditions in more than 75 countries around the world, hyaluronic acid treats multiple medical
conditions, including those associated with the eye and the knee, and has been used for more than
20 years. The same formulation of BOTOX ® was approved by the FDA in 2002 as BOTOX ® Cosmetic
for the temporary improvement in the appearance of moderate to severe frown lines between the
brows in people 18 to 65 years of age.
Physicians often will use a combination of products to obtain a desired facial rejuvenation look that is
natural, expressive and fresh. With more than 55 years of experience providing high-quality, sciencebased
products, Allergan, together with its INAMED division, is the only company with a global facial
aesthetics franchise offering the most comprehensive array of innovative products, including:
BOTOX ® Cosmetic; JUVÉDERM dermal filler and other hyaluronic acid dermal fillers; the only
collagen-based dermal fillers (non-animal based COSMODERM ® and COSMOPLAST ® collagen
dermal fillers) that require no prior allergy testing; and physician-dispensed products such as
PREVAGE ® MD anti-aging treatment, which contains the most powerful antioxidant available in a skin
care product today.
Like BOTOX ® Cosmetic, JUVÉDERM should only be administered by a trained and qualified health
care provider. Further product and prescribing information is available by visiting
www.JuvedermComingSoon.com and www.BotoxCosmetic.com.
INAMED, a division of Allergan, has an exclusive licensing agreement with the Corneal Group for the
JUVÉDERM dermal filler family of products and future product line extensions in the United States,
Canada and Australia and a non-exclusive agreement in certain strategically important European
markets under the name HYDRAFILL dermal filler.
JUVÉDERM Clinical Studies
The FDA’s approval of JUVÉDERM dermal filler was based on data from a double-blind,
randomized and controlled clinical trial. A total of 439 subjects were followed for six months after
injection with one of three JUVÉDERM formulations (JUVÉDERM 24HV, JUVÉDERM 30HV,
JUVÉDERM 30) in one nasolabial fold, and ZYPLAST ® bovine-based collagen in the other.
JUVÉDERM dermal filler was found to provide a more persistent wrinkle correction than ZYPLAST ®
over the 6-month course of the study, with up to 90% of subjects maintaining at least a 1-grade
improvement in nasolabial fold correction with JUVÉDERM compared to 36-45% with ZYPLAST ®

ovine-based collagen. At the conclusion of the study, up to 88% of subjects expressed a preference
for JUVÉDERM dermal filler while only 5-12% expressed a preference for ZYPLAST ® collagen. In
addition, among non-Caucasian patients (all Fitzpatrick Skin Types), JUVÉDERM was found safe
and effective and demonstrated no increased risk of hyperpigmentation or hypertrophic scarring.
Important JUVÉDERM Dermal Filler Safety Information
In clinical studies, adverse events were usually mild to moderate in nature, did not require
intervention and lasted seven days or less. The most common side effects included temporary
injection site reactions including redness, pain/tenderness, firmness, swelling, lumps and bumps and
bruising. For complete patient safety information, please visit www.JuvedermComingSoon.com.
Important BOTOX ® Cosmetic Safety Information
BOTOX ® Cosmetic is indicated for the temporary improvement in the appearance of moderate to
severe frown lines between the brows in people 18 to 65 years of age. BOTOX ® Cosmetic is the only
product of its type approved by the FDA for the treatment of moderate to severe frown lines between
the brows. BOTOX ® Cosmetic should only be administered by a trained and qualified health care
provider.
Serious heart problems and serious allergic reactions have been reported rarely. If you think you are
having an allergic reaction or other unusual symptoms, such as difficulty swallowing, speaking or
breathing, call your doctor immediately. The most common side effects following injection are
temporary eyelid droop and nausea. Localized pain, infection, inflammation, tenderness, swelling,
redness and/or bleeding/bruising may be associated with the injection. Patients with certain
neuromuscular disorders such as ALS, myasthenia gravis or Lambert-Eaton syndrome may be at
increased risk of serious side effects.
Forward-Looking Statements
This press release contains "forward-looking statements", including the statements by Dr. Scott
Whitcup and Dr. Gary Monheit and other statements regarding the effectiveness of JUVÉDERM ,
BOTOX ® Cosmetic and BOTOX ® . These statements are based on current expectations of future
events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize,
actual results could vary materially from Allergan's expectations and projections. Risks and
uncertainties include, among other things, general industry and pharmaceutical market conditions;
technological advances and patents attained by competitors; challenges inherent in the research and
development and regulatory processes; challenges related to new product marketing, such as the
unpredictability of market acceptance for new pharmaceutical and biologic products and/or the
acceptance of new indications for such products; inconsistency of treatment results among patients;
potential difficulties in manufacturing a new product formulation; and governmental laws and
regulations affecting domestic and foreign operations. Additional information concerning these and
other risk factors can be found in press releases issued by Allergan, as well as Allergan’s public
periodic filings with the Securities and Exchange Commission, including the discussion under the
heading “Risk Factors” in Allergan’s 2005 Form 10-K and Allergan’s Form 10-Q for the quarter ended
March 31, 2006. Copies of Allergan’s press releases and additional information about Allergan is
available on the World Wide Web at www.allergan.com or you can contact the Allergan Investor
Relations Department by calling 1-714-246-4636.
About Allergan, Inc.
With more than 55 years of experience providing high-quality, science-based products, Allergan, Inc.,
with headquarters in Irvine, California, develops and commercializes products in the ophthalmology,

neurosciences, medical dermatology, medical aesthetics, obesity intervention and other specialty
markets that deliver value to its customers, satisfy unmet medical needs, and improve patients’ lives.
ZYPLAST ® , COSMODERM ® , COSMOPLAST ® , JUVEDERM and HYDRAFILL ® are marks owned by INAMED
Corporation.
BOTOX ® , PREVAGE ® and TOTAL FACIAL REJUVENATION are marks owned by Allergan, Inc.
Allergan, Inc. Contacts:
Caroline Van Hove, Allergan
Jim Hindman, Allergan
Joann Bradley, Allergan
714-246-5134 (media)
714-246-4636 (investors)
714-246-4766 (investors)
# # #